DNX 515
Alternative Names: DNX-515Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator DNX Biopharmaceuticals
- Class Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for research development in Autoimmune-disorders in USA
- 28 Oct 2024 No recent reports of development identified for research development in Inflammation in USA
- 18 Sep 2020 DNX 515 is available for licensing as of 18 Sep 2020. http://www.dnxbio.com/partnering-licensing.html